Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 14/20 | 0.67 |
| ▸ | RAD52 | P43351 | 1/20 | 0.66 |
| ▸ | BRD4 | O60885 | 5/20 | 0.61 |
| ▸ | BRDT | Q58F21 | 5/20 | 0.61 |
| ▸ | TTK | P33981 | 4/20 | 0.58 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.54 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.54 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.53 |
| ▸ | PLK4 | O00444 | 1/20 | 0.53 |
| ▸ | GAK | O14976 | 1/20 | 0.53 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1203621 | 0.95 | PLK1 (0.74) | PLK1RAD52BRD4BRDTTTK | |
| SCHEMBL3547133 | 0.94 | RAD52 (0.74) | PLK1RAD52BRD4BRDTTTK | |
| SCHEMBL1203349 | 0.94 | PLK1 (0.69) | PLK1RAD52BRD4BRDTTTK | |
| SCHEMBL1204132 | 0.93 | PLK1 (0.68) | PLK1RAD52BRD4BRDTTTK | |
| SCHEMBL1203986 | 0.92 | PLK1 (0.71) | PLK1RAD52BRD4BRDTTTK | |
| SCHEMBL1203461 | 0.91 | PLK1 (0.71) | PLK1RAD52BRD4BRDTTTK | |
| SCHEMBL1203641 | 0.90 | PLK1 (0.67) | PLK1RAD52BRD4BRDTTTK | |
| SCHEMBL3549824 | 0.90 | RAD52 (0.76) | PLK1RAD52BRD4BRDTTTK | |
| SCHEMBL1203263 | 0.89 | PLK1 (0.67) | PLK1RAD52BRD4BRDTTTK | |
| SCHEMBL3542341 | 0.89 | PLK1 (0.60) | PLK1RAD52BRD4BRDTTTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | claimed |
| EP-2610256-A1 | Pyrimidine derivatives as protein kinase inhibitors | Cyclacel Limited (GB) | 2013-07-03 | — | — | EP | claimed |
| US-11001594-B2 | Heterocyclic modulators of HIF activity for treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-05-11 | — | — | US | disclosed |
| US-20190270753-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | UNIV TEXAS (US) | 2019-09-05 | — | — | US | disclosed |
| US-10208059-B2 | Heterocyclic modulators of HIF activity for treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-02-19 | — | — | US | disclosed |
| EP-2888255-B1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | UNIV TEXAS (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20170121342-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM | 2017-05-04 | — | — | US | disclosed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-9481692-B2 | Heterocyclic modulators of HIF activity for treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-11-01 | — | — | US | disclosed |
| US-20140066424-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center (US) | 2014-03-06 | — | — | US | disclosed |
| EP-2205603-B1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LTD (GB) | 2014-01-15 | — | — | EP | disclosed |
| US-8563542-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| US-8563542-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| US-8563542-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| EP-2610256-A1 | Pyrimidine derivatives as protein kinase inhibitors | Cyclacel Limited (GB) | 2013-07-03 | — | — | EP | disclosed |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270753-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, HIF1A, EGLN3 | PLK1 3752/4885RAD52 2307/4885BRD4 865/4885 |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CDK7, CDK9, CDK8 | PLK1 355/4885RAD52 2823/4885BRD4 589/4885 |
| US-20140066424-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, HIF1A, EGLN3 | PLK1 3752/4885RAD52 2307/4885BRD4 865/4885 |
| US-10208059-B2 | Heterocyclic modulators of HIF activity for treatment of disease | HIF1AN, HIF1A, EGLN3 | PLK1 3752/4885RAD52 2307/4885BRD4 865/4885 |
| US-11001594-B2 | Heterocyclic modulators of HIF activity for treatment of disease | HIF1AN, HIF1A, EGLN3 | PLK1 3752/4885RAD52 2307/4885BRD4 865/4885 |
| US-20170121342-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, HIF1A, EGLN3 | PLK1 3752/4885RAD52 2307/4885BRD4 865/4885 |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | DCK, DTYMK, TK1 | PLK1 23/4885RAD52 1278/4885BRD4 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.